Trial Profile
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Burkitt's lymphoma; Diffuse lymphoma; Follicular lymphoma; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 07 Nov 2019 Status changed from active, no longer recruiting to completed.
- 13 Jan 2018 Planned End Date changed from 1 Dec 2014 to 1 May 2018.
- 13 Jan 2018 Status changed from recruiting to active, no longer recruiting.